335 related articles for article (PubMed ID: 19109993)
1. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
[TBL] [Abstract][Full Text] [Related]
2. Inverse agonism at serotonin and cannabinoid receptors.
Aloyo VJ; Berg KA; Clarke WP; Spampinato U; Harvey JA
Prog Mol Biol Transl Sci; 2010; 91():1-40. PubMed ID: 20691957
[TBL] [Abstract][Full Text] [Related]
3. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
[TBL] [Abstract][Full Text] [Related]
4. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Prog Brain Res; 2008; 172():287-305. PubMed ID: 18772038
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of pyridazinone-based 5-HT(2C) agonists.
Allerton CM; Andrews MD; Blagg J; Ellis D; Evrard E; Green MP; Liu KK; McMurray G; Ralph M; Sanderson V; Ward R; Watson L
Bioorg Med Chem Lett; 2009 Oct; 19(19):5791-5. PubMed ID: 19716297
[TBL] [Abstract][Full Text] [Related]
6. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.
Bubar MJ; Cunningham KA
Prog Brain Res; 2008; 172():319-46. PubMed ID: 18772040
[TBL] [Abstract][Full Text] [Related]
7. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
Leggio GM; Cathala A; Neny M; Rouge-Pont F; Drago F; Piazza PV; Spampinato U
J Neurochem; 2009 Oct; 111(2):614-23. PubMed ID: 19702657
[TBL] [Abstract][Full Text] [Related]
8. Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.
Seimandi M; Bockaert J; Marin P
Methods Enzymol; 2010; 485():61-79. PubMed ID: 21050911
[TBL] [Abstract][Full Text] [Related]
9. 5-HT2C receptor agonists as an innovative approach for psychiatric disorders.
Rosenzweig-Lipson S; Dunlop J; Marquis KL
Drug News Perspect; 2007 Nov; 20(9):565-71. PubMed ID: 18176661
[TBL] [Abstract][Full Text] [Related]
10. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
Chanrion B; Mannoury la Cour C; Gavarini S; Seimandi M; Vincent L; Pujol JF; Bockaert J; Marin P; Millan MJ
Mol Pharmacol; 2008 Mar; 73(3):748-57. PubMed ID: 18083778
[TBL] [Abstract][Full Text] [Related]
11. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
Herrick-Davis K; Grinde E; Teitler M
J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
[TBL] [Abstract][Full Text] [Related]
12. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
Miller KJ; Wu GY; Varnes JG; Levesque P; Li J; Li D; Robl JA; Rossi KA; Wacker DA
Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
[TBL] [Abstract][Full Text] [Related]
13. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
14. Novel actions of inverse agonists on 5-HT2C receptor systems.
Berg KA; Stout BD; Cropper JD; Maayani S; Clarke WP
Mol Pharmacol; 1999 May; 55(5):863-72. PubMed ID: 10220565
[TBL] [Abstract][Full Text] [Related]
15. Role of spinal 5-HT2 receptor subtypes in quipazine-induced hindlimb movements after a low-thoracic spinal cord transection.
Ung RV; Landry ES; Rouleau P; Lapointe NP; Rouillard C; Guertin PA
Eur J Neurosci; 2008 Dec; 28(11):2231-42. PubMed ID: 19019202
[TBL] [Abstract][Full Text] [Related]
16. Differences in agonist-independent and -dependent 5-hydroxytryptamine2C receptor-mediated cell division.
Westphal RS; Sanders-Bush E
Mol Pharmacol; 1996 Mar; 49(3):474-80. PubMed ID: 8643087
[TBL] [Abstract][Full Text] [Related]
17. Regulation of serotonin 5-HT2C receptors by chronic ligand exposure.
Devlin MG; Smith NJ; Ryan OM; Guida E; Sexton PM; Christopoulos A
Eur J Pharmacol; 2004 Sep; 498(1-3):59-69. PubMed ID: 15363976
[TBL] [Abstract][Full Text] [Related]
18. 5-HT2C receptor modulators: a patent survey.
Lee J; Jung ME; Lee J
Expert Opin Ther Pat; 2010 Nov; 20(11):1429-55. PubMed ID: 20849206
[TBL] [Abstract][Full Text] [Related]
19. Atypical antipsychotics and inverse agonism at 5-HT2 receptors.
Sullivan LC; Clarke WP; Berg KA
Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975
[TBL] [Abstract][Full Text] [Related]
20. Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice.
Fletcher PJ; Tampakeras M; Sinyard J; Slassi A; Isaac M; Higgins GA
Neuropharmacology; 2009 Sep; 57(3):259-67. PubMed ID: 19501602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
